Toft Group Completes Executive Search for Natera, Inc. (NYSE: NTRA)

Natera

Executive search firm Toft Group has placed Ms. Sylvia Kainz as Senior Director, Sales Operations & Strategy at Natera, Inc., in San Carlos, CA. Ms. Kainz brings 20 years of experience in strategy and operations, having worked in a diverse range of industries across high-tech, manufacturing, retail, and management consulting. She most recently served with InsideView, the CRM intelligence leader, as VP of Business Operations. Prior, she led operations and branding strategies for companies including United Technologies, Grid Dynamics, and Bradford Technologies. Ms. Kainz also served 6 years as Director with Accenture, one of the top management consulting firms in the country. Ms. Kainz earned her MBA from Harvard University and MS degrees from Tufts University and Zurich University.

About Natera, Inc.

Natera is a leading genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its direct sales force, laboratory distribution partners, and licensees that can run tests in their own laboratories and have the data analyzed through Natera's cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.